Citi kept a Buy rating on Mersana Therapeutics (MRSN) with a $5 price target following a transfer of coverage. The company expects to share initial data from the XMT-1660 Phase 1 by the end of 2024, the analyst tells investors in a research note. The firm sees the readout as a “significant catalyst which may reinvigorate shares.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN: